Inhibition of albendazole crystallization in poly(vinylpyrrolidone) solid molecular dispersions

Pharmazie

Volumn 61, Issue 7, 2006, Pages 618-624

  Kalaiselvan, R ^a   Mohanta, G P ^a   Manna, P K ^a   Manavalan, R ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; COPOLYMER; POLYMER; POLYVINYL ACETATE; POVIDONE;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG STABILITY; GLASS TRANSITION TEMPERATURE; HIGH TEMPERATURE; HYDROGEN BOND; MOLECULAR WEIGHT; STORAGE TEMPERATURE;

ALBENDAZOLE; ANTHELMINTICS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HYDROGEN BONDING; PHARMACEUTIC AIDS; POVIDONE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY;

EID: 33746225530     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
2. Brekner MJ, Schneider HA, Cantow HJ (1988) Approach to the composition dependence of the glass transition temperature of compatible polymer blends. Polymer 29: 78-85.
3. Chiou WL, Riegelman S (1971) Preparation and dissolution characteristics of several fast release solid dispersions of griseofulvin. J Pharm Sci 60: 1281-1302.
4. Crowley KJ, Zografi G (2002) Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J Pharm Sci 90: 2150-2165.
5. Dwivedi AM (2002) Residual solvent analysis in pharmaceuticals. Pharm Technol 27: 43-46.
6. Gordon M, Taylor JS (1952) Ideal copolymers and the second order transitions of synthetic rubbers 1. Noncrystalline copolymers. J Appl Chem 2: 493-500.
7. Horton RJ (1997) Albendazole in the treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 64: 79-93.
8. Hsu CC, Nguyen HM, Young DA, Brooks DA, Koe GS, Bewley TA, Pearlman R (1995) Surface denaturation at solid-void interface -a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperature. Pharm Res 12: 69-77.
9. Jung H, Medina L, Garcia L, Fuentes I, Esparza RM (1998) Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite, albendazole sulphoxide. J Pharm Pharmacol 50: 43-48.
10. Keramidas D, Mavridis G, Soutis M, Passalidis A (2004) Medical treatment of pulmonary hydatidosis: complications and surgical management. Pediatr Surg Int 19: 774-776.
11. Lecuit N, Oksenhendler E, Sarfati C (1994) The use of albendazole for disseminated microsporidian infection in patients with AIDS. Clin Infect Dis 19: 332-333.
12. Leuner C, Dressman J (2000) Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50: 47-60.
13. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3-25.
14. Lopez-Garcia ML, Torrado-Duran S, Torrado-Duran J, Martinez AR, Bolas F (1997) Albendazole versus ricobendazole against enteral and parenteral stages of Trichinella spiralis in mice., Int J Parasitol 27: 781-785.
15. Ma X, Taw J, Chiang CM (1996) Control of drug crystallization in transdermal matrix system. Int J Pharm 142: 115-119.
16. th ed., Lea & Febiger, Philadelphia, p. 331-569.
17. Matsumoto T, Zografi G (1999) Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728.
18. Misra PK, Kumar A, Agarwal U, Jagota SC (1995) A comparative clinical trial of albendazole vs metronidazole in giardiasis. Indian Pediatr 32: 291-294.
19. Mooter GVD, Brande VD, Augustijns P, Kinget R (1999) Glass forming properties of benzodiazepines and co-evaporate systems with poly(hydroxyethyl methacrylate). J Therm Anal Cal 57: 493-507.
20. Otsuka M, Kaneniwa N (1988) A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 36: 4026-4032.
21. Roos Y, Karel M (1991) Plasticizing effect of water on thermal behavior and crystallization of amorphous food models. J Food Sci 56: 38-43.
22. Saleki-Gerhardt A, Zografi G (1994) Nonisothermal crystallization of sucrose from the amorphous state. Pharm Res 11: 1166-1173.
23. g vs composition curves. Polymer 38: 1323-1337.
24. Sekikawa H, Nakano M, Arita T (1978) Inhibitory effect of poly(vinylpyrrolidone) on the crystallization of drugs. Chem Pharm Bull 26: 118-126.
25. Sekizaki H, Danjo K, Eguchi H, Yonezawa Y, Sunada H, Otsuka A (1995) Solid-state interaction of ibuprofen with polyvinylpyrrolidone. Chem Pharm Bull 43: 988-993.
26. Sertsou G, Butler J, Hempenstall J, Rades T (2002) Solvent change coprecipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug. J Pharm Pharmacol 54: 1041-1047.
27. th ed., John Wiley and Sons, New York, p. 102-104.
28. Taylor LS, Zografi G (1997) Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14: 1691-1698.
29. Wen H, New RRC, Craig PS (1993) Diagnosis and treatment of human hydatidosis. Br J Clin Pharmac 35: 565-574.
30. WHO Informal Working Group on Echinococcosis (1996) Guidelines for treatment of cystic alveolar echinococcosis in humans. Bull WHO 74: 231-242.
31. Yoshioka M, Hancock BC, Zografi G (1994) Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83: 1700-1705.
32. Yoshioka M, Hancock BC, Zografi G (1995) Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84: 983-986.
33. Ziller KH, Rupprecht H (1988) Control of crystal growth in drug suspensions. Drug Dev Ind Pharm 14: 2341-2370.